Allezoe Medical Holdings, Inc.
OTC Bulletin Board : ALZM

Allezoe Medical Holdings, Inc.

September 21, 2011 09:30 ET

Allezoe Medical Holdings (ALZM) To Acquire HPV Treatment Alternative

"See and Treat" Technology Offers Alternative to Controversial HPV Vaccine

BOCA RATON, FLORIDA--(Marketwire - Sept. 21, 2011) - Allezoe Medical Holdings, Inc. (OTCBB:ALZM) announced earlier this week that it has agreed to acquire patent pending technology that would enable healthcare providers to "see and treat" Human Papillomavirus (HPV), the most common sexually transmitted infection and a cause of cervical cancer, In addition to offering easy, affordable, and on-the-spot HPV diagnosis, the technology offers an important alternative to the HPV vaccine.

Currently HPV infects 233 Million women worldwide; one woman dies every 2 hours from cervical cancer. Many experts advocate for HPV vaccination, but unexplained deaths in some patients has caused alarm. The Centers for Disease Control and Prevention (CDC) has examined 35 deaths that occurred among young people who received the vaccine. While no causation has been established, many patients and parents are avoiding the vaccine option.

Prominent figures, most recently two U.S. Presidential candidates, have taken firm (and opposing) public stances, further highlighting the ongoing controversy about the HPV vaccine. For other reasons, including the vaccine's cost and the inconvenience of it being administered over a number of visits, many patients don't actually complete the series. Last year only 32 percent of teenage girls nationwide received all three shots needed to prevent HPV infection.

Allezoe CEO Michael Gelmon says, "With millions of existing HPV infections and the ease of passing the virus on, every minute spent debating the safety of solutions or having to coax patients into following through on treatment is resulting in unnecessary deaths. It is crucial to adopt an alternative that patients and their doctors can both embrace."

While popular, HPV vaccines do not treat existing HPV infections or HPV-associated diseases. Nor does the vaccine completely protect from all strains of HPV. Merck's Gardisil vaccine prevents 70% of virally-caused cervical cancer but may only have some effect against the other strains. The technology, equipment, and procedures (SureScreen™) Allezoe has announced are comprehensive in that a light-based exam identifies cells damaged by all known strains of HPV -- with 98% accuracy, in a single visit, and at low cost.

For those who receive the vaccine, Allezoe's technology serves as a natural complement, screening for HPV-related damage that occurred in the window before the vaccine was administered. Allezoe is forming a new wholly-owned subsidiary to see the technology, developed by Aequorea Vision Medical, through regulatory approvals and clearances, to be followed by a broad market release.

Gelmon says, "HPV is a pressing and widespread health issue. We intend to take the straightforward and cost-efficient option we are acquiring and commercialize it as soon as possible. The market need is there, and the solution is now in our hands."

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company's most recently filed form 10-K and Form 10-Q reports. The Company assumes no obligation to update the statements contained in this release except as required by applicable securities disclosure rules. The Company's SEC filings are available at

Contact Information